Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Author: D.P. Tashkin, MD, M.D. Roth, MD, P.J. Clements, MD, D.E. Furst, MD, D. Khanna, MD, E.C. Kleerup, MD, J. Goldin, MD, E. Arriola, PharmD, E.R. Volkmann, MD, et al
Date Published: July-2016
Source: The Lancet

12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvements than cyclophosphamide.